Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 13/20 | 0.47 |
| ▸ | APOB | P04114 | 5/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | UGCG | Q16739 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7083522 | 0.91 | RXFP1 (0.45) | MTTPAPOBHDAC1HDAC6RXFP1 | |
| SCHEMBL6800458 | 0.89 | MTTP (0.49) | MTTPAPOBGAASMO | |
| SCHEMBL6795009 | 0.86 | MTTP (0.55) | MTTPAPOBHDAC1RXFP1GAA | |
| SCHEMBL7613184 | 0.84 | MTTP (0.52) | MTTPAPOBHDAC1HDAC6RXFP1 | |
| SCHEMBL6799904 | 0.83 | MTTP (0.50) | MTTPAPOBGAASMO | |
| SCHEMBL6789351 | 0.83 | MTTP (0.49) | MTTPAPOBRXFP1UGCGGAA | |
| SCHEMBL6787835 | 0.82 | MTTP (0.47) | MTTPAPOBRXFP1UGCGSMO | |
| SCHEMBL7085681 | 0.81 | MTTP (0.47) | MTTPAPOBRXFP1UGCGGAA | |
| SCHEMBL7610927 | 0.80 | MTTP (0.51) | MTTPAPOBHDAC1RXFP1 | |
| SCHEMBL6796384 | 0.80 | SMO (0.55) | MTTPAPOBGAASMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | MTTP 363/4885APOB 1/4885HDAC1 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.